Dr Agarwals Health Care Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹530Cr
- +23% YoY
- +6.2% QoQ
- Net profit
- ₹44Cr
- +57.1% YoY
- +22.2% QoQ
- Margin
- 27%
- 0 pp YoY
- 0 pp QoQ
Guidance rank: #12 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Dr. The company aims to add 55 to 60 new facilities annually, expanding its network by about 20% each year, supporting revenue growth.
From Dr Agarwals Health Care Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Dr. Agarwal’s Health Care Limited plans to add 55 to 60 new facilities annually, aiming to increase network size by roughly 20% each year.
- Same-store sales growth is strong, exceeding 13.5%, reflecting healthy organic growth.
- Surgical services continue to be the main revenue driver, with 67% contribution to group revenue.
- High-end cataract surgeries contribute around 28% of overall cataract surgery revenue, indicating premiumization.
- Volume growth and value growth both contribute approximately equally (~6.5% each) to overall growth.
- Newer centers take about 15-18 months to break even, while core market facilities break even in 6-7 months, averaging about 12 months overall.
2 more points from Dr Agarwals Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dr Agarwals Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Annual addition of 55 to 60 new facilities planned, with network growth targeted at ~20% per year.
- CAPEX per facility type:
- Surgical secondary facility: Rs. 5.5 to 6 crores
- Tertiary facility: Rs. 11 to 12 crores
- Primary facility: ~Rs. 35 lakhs
- Ethiopia subsidiary: Exploring entry with organic growth; feasibility study ongoing with no CAPEX estimates yet; funding fully by Orbit entity.
- Subsidiary facility (Cathedral Road): CAPEX spend Rs. 35 crores out of Rs. 70 crores committed; licensing and approvals expected by Q2 FY2027.
2 more points from Dr Agarwals Health Care Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Agarwals Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Dr Agarwals Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Dr Agarwals Health Care Ltd — Quarterly revenue & net profit
Dr Agarwals Health Care Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 530 | 431 | +23% | 499 | +6.2% |
| Operating profit (EBITDA) | 144 | 115 | +25.2% | 136 | +5.9% |
| Operating margin | 27% | 27% | 0 pp | 27% | 0 pp |
| Profit before tax | 65 | 41 | +58.5% | 54 | +20.4% |
| Net profit (PAT) | 44 | 28 | +57.1% | 36 | +22.2% |
| EPS (₹) | 1.07 | 0.72 | +48.6% | 1.10 | -2.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹655 Cr, net profit ₹57 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Agarwal's Hea's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
Earlier calls (1)
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dr Agarwals Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Agarwals Health Care Ltd Q3 FY26 results?
Dr. The company aims to add 55 to 60 new facilities annually, expanding its network by about 20% each year, supporting revenue growth.
What is Dr Agarwals Health Care Ltd share price analysis?
Dr Agarwals Health Care Ltd currently shows a neutral. The stock trades at a P/E of 111.9 with a market cap of ₹16,519 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Agarwals Health Care Ltd planning capital expenditure?
Annual addition of 55 to 60 new facilities planned, with network growth targeted at ~20% per year.
Keep Dr Agarwals Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
